Search Results

You are looking at 1 - 10 of 1,535 items for :

Clear All
Full access

John A. Glaspy

in gastric cancer cell growth, angiogenesis, and vessel maturation . J Natl Cancer Inst 2004 ; 96 : 946 – 956 . 20 Dunst J Kuhnt T Strauss HG . Anemia in cervical cancers: impact on survival, patterns of relapse, and association with

Full access

Vishwajith Sridharan, Vinayak Muralidhar, Danielle N. Margalit, Roy B. Tishler, James A. DeCaprio, Manisha Thakuria, Guilherme Rabinowits and Jonathan D. Schoenfeld

carries a high risk of spreading to regional lymph nodes. Nodal recurrences and distant metastases are common, with limited survival for patients with advanced disease. 5 , 6 Treatment of localized MCC is variable, focusing on wide local excision

Full access

Nikolai A. Podoltsev, Mengxin Zhu, Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Amy J. Davidoff, Scott F. Huntington, Smith Giri, Steven D. Gore and Xiaomei Ma

Background Essential thrombocythemia (ET) is a clonal myeloproliferative neoplasm (MPN) characterized by persistently elevated platelet counts. The median age at diagnosis is 68 years 1 and median survival is 19.8 years, which is inferior to that

Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch and Vivien W. Chen

, luminal B, basal-like (triple-negative: ER–/PR–/HER2–), and HER2+/ER–. 1 , 4 These subtypes vary by race and influence survival rate. 5 When physicians prescribe appropriate adjuvant systemic therapies (ASTs) for patients with breast cancer, molecular

Full access

Anuhya Kommalapati, Sri Harsha Tella, Adams Kusi Appiah, Lynette Smith and Apar Kishor Ganti

. The Intergroup 0139 study demonstrated an improvement in 5-year progression-free survival and local control with surgical resection after neoadjuvant chemoradiotherapy. 6 A trend toward improved overall survival (OS) was seen in the surgery group

Full access

Sujana Movva, Margaret von Mehren, Eric A. Ross and Elizabeth Handorf

Background Soft tissue sarcomas (STS) are uncommon tumors of the connective tissues. According to the current AJCC staging system, patients with stage III disease (large, deep, high-grade) have an expected overall survival (OS) of

Full access

Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A. Nelson and Yi-Jen Chen

poor survival outcomes with CRT in the absence of curative surgery, although patients receiving CRT in these studies experienced significant treatment toxicity. 17 – 19 Both chemotherapy and radiation therapy (RT) techniques have advanced significantly

Full access

Talia Golan, Tal Sella, Ofer Margalit, Uri Amit, Naama Halpern, Dan Aderka, Einat Shacham-Shmueli, Damien Urban and Yaacov Richard Lawrence

Background In recent years, substantial advances in the diagnosis and treatment of cancer have increased survival rates for most cancers. Despite this progress, death rates for pancreatic cancer (PDAC), the fourth-leading cause of cancer death

Full access

Amit G. Singal, Akbar K. Waljee, Nishant Patel, Emerson Y. Chen, Jasmin A. Tiro, Jorge A. Marrero and Adam C. Yopp

transplant, were excluded because of the lack of therapeutic options associated with a survival benefit. Similarly, patients with locally advanced (ie, tumor thrombus) or metastatic disease before 2008 were excluded given the lack of proven therapeutic

Full access

Erin E. Hahn, Michael K. Gould, Corrine E. Munoz-Plaza, Janet S. Lee, Carla Parry and Ernest Shen

survival (OS). 5 – 12 Effectively managing CRC treatment in patients with comorbid conditions is an important clinical issue. Determining how comorbid conditions cluster together, impact treatment selection, and ultimately influence prognosis in CRC is a